2017 Section 7 Green Book

Cheung et al

patients with squamous cell cancer of the head and neck. Nuklearmedizin . 2000;39:246-250. 17. Goerres GW, Schmid DT, Bandhauer F, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg . 2004;130:105-109. 18. Gupta T, Jain S, Agarwal JP, et al. Diagnostic performance of response assessment FDG-PET/CT in patients with head and neck squamous cell carcinoma treated with high-precision defi- nitive (chemo) radiation. Radiother Oncol . 2010;97:194-199. 19. Inohara H, Enomoto K, Tomiyama Y, et al. The role of CT and 18F-FDG PET in managing the neck in node-positive head and neck cancer after chemoradiotherapy. Acta Otolaryngol . 2009; 129:893-899. 20. Ito K, Yokoyama J, Kubota K, Morooka M, Shiibashi M, Matsuda H. 18F-FDG versus 11C-choline PET/CT for the ima- ging of advanced head and neck cancer after combined intra- arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence. Eur J Nucl Med Mol Imaging . 2010;37:1318-1327. 21. Kim SY, Lee S-W, Nam SY, et al. The feasibility of 18F-FDG PET scans 1 month after completing radiotherapy of squamous cell carcinoma of the head and neck. J Nucl Med . 2007;48:373-378. 22. Kishino T, Hoshikawa H, Nishiyama Y, Yamamoto Y, Mori N. Usefulness of 3 # -deoxy-3 # -18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer. J Nucl Med . 2012;53:1521-1527. 23. Kitagawa Y, Nishizawa S, Sano K, et al. Prospective compari- son of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. J Nucl Med . 2003;44:198-206. 24. Kubota K, Yokoyama J, Yamaguchi K, et al. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/ CT. Eur J Nucl Med Mol Imaging . 2004;31:590-595. 25. Li P, Zhuang H, Mozley PD, et al. Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG posi- tron emission tomography. Clin Nucl Med . 2001;26:131-135. 26. McCollum AD, Burrell SC, Haddad RI, et al. Positron emis- sion tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and defini- tive chemoradiotherapy in head and neck cancer. Head Neck . 2004;26:890-896. 27. Moeller BJ, Rana V, Cannon BA, et al. Prospective risk- adjusted [18F] fluorodeoxyglucose positron emission tomogra- phy and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol . 2009;27:2509-2515. 28. Mori M, Tsukuda M, Horiuchi C, et al. Efficacy of fluoro-2- deoxy-D-glucose positron emission tomography to evaluate responses to concurrent chemoradiotherapy for head and neck squamous cell carcinoma. Auris Nasus Larynx . 2011;38:724-729. 29. Nam SY, Lee S-W, Im KC, et al. Early evaluation of the response to radiotherapy of patients with squamous cell carci- noma of the head and neck using 18 FDG-PET. Oral Oncol 2005;41:390-395. 30. Nayak JV, Walvekar RR, Andrade RS, et al. Deferring planned neck dissection following chemoradiation for stage IV

3. Gregoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clini- cal practice guidelines for diagnosis, treatment and follow-up. Ann Oncol . 2010;21(suppl 5):v184-v186. 4. Ang KK, Trotti A, Brown BW, et al. Randomized trial addres- sing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys . 2001;51:571-578. 5. Koness RJ, Glicksman A, Liu L, et al. Recurrence patterns with concurrent platinum-based chemotherapy and accelerated hyperfractionated radiotherapy in stage III and IV head and neck cancer patients. Am J Surg . 1997;174:532-535. 6. Gourin CG, Watts TL, Williams HT, Patel VS, Bilodeau PA, Coleman TA. Identification of distant metastases with positron–emission tomography-computed tomography in patients with previously untreated head and neck cancer. Laryngoscope . 2008;118:671-675. 7. Perlow A, Bui C, Shreve P, Sundgren PC, Teknos TN, Mukherji SK. High incidence of chest malignancy detected by FDG PET in patients suspected of recurrent squamous cell car- cinoma of the upper aerodigestive tract. J Comput Assist Tomogr . 2004;28:704-709. 8. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer . 1994;73:187-190. 9. Salaun PY, Abgral R, Querellou S, et al. Does 18fluoro-fluorodeox- yglucose positron emission tomography improve recurrence detec- tion in patients treated for head and neck squamous cell carcinoma with negative clinical follow-up? Head Neck . 2007;29:1115-1120. 10. Whiting P, Rutjes AW, Dinnes J, Reitsma J, Bossuyt PM, Kleijnen J. Development and validation of methods for asses- sing the quality of diagnostic accuracy studies. Health Technol Assess . 2004;8:iii, 1-234. 11. Brkovich VS, Miller FR, Karnad AB, Hussey DH, McGuff HS, Otto RA. The role of positron emission tomography scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiotherapy. Laryngoscope . 2006; 116:855-858. 12. Ceulemans G, Voordeckers M, Farrag A, Verdries D, Storme G, Everaert H. Can 18-FDG-PET during radiotherapy replace post-therapy scanning for detection/demonstration of tumor response in head-and-neck cancer? Int J Radiat Oncol Biol Phys . 2011;81:938-942. 13. Chaiken L, Rege S, Hoh C, et al. Positron emission tomogra- phy with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys . 1993;27:455-464. 14. Conessa C, Foehrenbach H, Herve´ S, Poncet J-L. FDG-PET scan in local follow-up of irradiated head and neck squamous cell carcinomas. Ann Otol Rhinol Laryngol . 2004;113:628-635. 15. Fakhry N, Jacob T, Paris J, et al. Contribution of 18-F-FDG PET for detection of head and neck carcinomas with an unknown primary tumor. Ann Otolaryngol Chir Cervicofac . 2006;123:17-25. 16. Goerres GW, Haenggeli CA, Allaoua M, et al. Direct compari- son of F-18-FDG PET and ultrasound in the follow-up of

32